definiens: shall mean, collectively, ( i ) the License Agreement dated December 23, 2002 byand among SCR Pharmatop S.A. and Bristol - Myers Squibb Company ; ( ii ) the IV APAP Agreement ( U.S. and Canada)dated February 21, 2006 by and between the Company and Bristol - Myers Squibb Company ; ( iii ) the LicenseAgreement dated November 27, 2012 by and between the Company and SCR Pharmatop S.A. and PaddockLaboratories, LLC and Perrigo Company ; ( iv ) the Settlement Agreement dated November 27, 2012 by and between theCompany and SCR Pharmatop S.A. and Paddock Laboratories, LLC and Perrigo Company ; and ( v ) the settlementagreement and binding term sheet, each dated January 28, 2014, among the Company, Sandoz, Inc., Sandoz AG, Neogen International N.V. and APC Pharmaceuticals, LLC